Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan I Epstein

Showing results (421-430 of 635) with videos related to

Pageof 64
Sort By:
Urology|January 18, 2006
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostateMark L Gonzalgo, Patrick J Bastian, Leslie A Mangold, et al.
The American Journal of Surgical Pathology|August 27, 2016
TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic HeterogeneityPedram Argani, Victor E Reuter, Lei Zhang, et al.
BJU International|March 8, 2013
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillanceJeffrey K Mullins, David Bonekamp, Patricia Landis, et al.
Human Pathology|July 23, 2011
Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic centerThomas K Lee, Alcides Chaux, Sarah Karram, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 11, 2019
Extramammary Paget Disease of the Scrotum: A Contemporary Clinicopathologic Analysis of 20 Cases in the United StatesMaryam Shabihkhani, Pallavi Patil, Belkiss Murati Amador, et al.
Histopathology|October 10, 2019
SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumoursDeepthi Hoskoppal, Jonathan I Epstein, Allen M Gown, et al.
Journal of the National Cancer Institute|November 2, 2006
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curabilityH Ballentine Carter, Luigi Ferrucci, Anna Kettermann, et al.
The Journal of Urology|July 4, 2006
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/mlDanil V Makarov, Elizabeth B Humphreys, Leslie A Mangold, et al.
European Urology|October 13, 2015
Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate SurgeryJeffrey J Tosoian, Debasish Sundi, Bruce J Trock, et al.
Urology|June 19, 2007
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005Danil V Makarov, Bruce J Trock, Elizabeth B Humphreys, et al.
Pageof 64

Showing results (421-430 of 635) with videos related to

Sort By:
Pageof 64
Urology|January 18, 2006
Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostateMark L Gonzalgo, Patrick J Bastian, Leslie A Mangold, et al.
The American Journal of Surgical Pathology|August 27, 2016
TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic HeterogeneityPedram Argani, Victor E Reuter, Lei Zhang, et al.
BJU International|March 8, 2013
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillanceJeffrey K Mullins, David Bonekamp, Patricia Landis, et al.
Human Pathology|July 23, 2011
Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic centerThomas K Lee, Alcides Chaux, Sarah Karram, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 11, 2019
Extramammary Paget Disease of the Scrotum: A Contemporary Clinicopathologic Analysis of 20 Cases in the United StatesMaryam Shabihkhani, Pallavi Patil, Belkiss Murati Amador, et al.
Histopathology|October 10, 2019
SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumoursDeepthi Hoskoppal, Jonathan I Epstein, Allen M Gown, et al.
Journal of the National Cancer Institute|November 2, 2006
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curabilityH Ballentine Carter, Luigi Ferrucci, Anna Kettermann, et al.
The Journal of Urology|July 4, 2006
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/mlDanil V Makarov, Elizabeth B Humphreys, Leslie A Mangold, et al.
European Urology|October 13, 2015
Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate SurgeryJeffrey J Tosoian, Debasish Sundi, Bruce J Trock, et al.
Urology|June 19, 2007
Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005Danil V Makarov, Bruce J Trock, Elizabeth B Humphreys, et al.
Pageof 64